Literature DB >> 11180597

Data mining: Efficiency of using sequence databases for polymorphism discovery.

D Cox1, C Boillot, F Canzian.   

Abstract

An open question in research on Single Nucleotide Polymorphisms (SNPs) is, what is the percentage of true SNPs found by in silico pre-screening? To this end, we selected 13 genes, and determined the complete collection of "true" polymorphisms, or polymorphisms experimentally detected, existing in these genes in our laboratory using Denaturing High Performance Liquid Chromatography (DHPLC) and fluorescent sequencing, or in other laboratories using comparable methods. The genes studied by our group were PTGS2, IGFBP1, IGFBP3, and CYP19. GenBank sequence information was then aligned using two methods, and sequence differences termed "candidate" polymorphisms. We then compared the series of SNPs obtained experimentally and in silico and we have found that in silico methods are relatively specific (up to 55% of candidate SNPs found by SNPFinder have been discovered by experimental procedure) but have low sensitivity (not more than 27% of true SNPs are found by in silico methods). Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180597     DOI: 10.1002/1098-1004(200102)17:2<141::AID-HUMU6>3.0.CO;2-1

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  6 in total

1.  Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms.

Authors:  Tianhua Niu; Zhaohui S Qin; Xiping Xu; Jun S Liu
Journal:  Am J Hum Genet       Date:  2001-11-26       Impact factor: 11.025

2.  Denaturing high performance liquid chromatography: high throughput mutation screening in familial hypertrophic cardiomyopathy and SNP genotyping in motor neurone disease.

Authors:  B Yu; N A Sawyer; M Caramins; Z G Yuan; R B Saunderson; R Pamphlett; D R Richmond; R W Jeremy; R J Trent
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

3.  Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease.

Authors:  David-G Cox; J-Bart-A Crusius; Petra-H-M Peeters; H-Bas Bueno-de-Mesquita; A-Salvador Pena; Federico Canzian
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

4.  Associations between ALOX, COX, and CRP polymorphisms and breast cancer among Hispanic and non-Hispanic white women: The breast cancer health disparities study.

Authors:  Avonne E Connor; Richard N Baumgartner; Kathy B Baumgartner; Christina M Pinkston; Stephanie D Boone; Esther M John; Gabriela Torres-Mejía; Lisa M Hines; Anna R Giuliano; Roger K Wolff; Martha L Slattery
Journal:  Mol Carcinog       Date:  2014-10-22       Impact factor: 4.784

5.  A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.

Authors:  David G Cox; Julie Buring; Susan E Hankinson; David J Hunter
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

6.  Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer.

Authors:  D G Cox; C Pontes; E Guino; M Navarro; A Osorio; F Canzian; V Moreno
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.